Say Hello!
Don’t be shy.

   

XenoGesis Tag

XenoGesis has been acquired by leading drug discovery CRO, Sygnature Discovery, strengthening the combined DMPK offering and enhancing existing capabilities and expertise. This latest acquisition by Sygnature serves to meet the increasing demand for DMPK services and boosts the company’s reach into the pre-clinical space. XenoGesis’ novel...

Supporting the discovery and development of new therapeutics during the pandemic Nottingham-based contract research organisations (CROs) have strengthened their existing links to work together and support the discovery and development of new therapeutics during the pandemic. Many businesses have been impacted by the restrictions on the movement...

XenoGesis Founder and CEO, Richard Weaver, has been named Director of the Year at the Institute of Directors East Midlands Awards 2019, in the SME business (Small) category. Held at Winstanley House, Leicestershire, the awards celebrated the most dynamic and inspiring directors in the region. Forty-six of...

XenoGesis has appointed Dr Rachel Hemsley as global head of business development in a drive to support its ambitious growth plans. The Nottingham-based biotechnology company is the UK's largest independent laboratory-based contract research organisation (CRO) specialising in preclinical drug metabolism and pharmacokinetics (DMPK) – enabling it to provide expert...

X
X
X
X